Our HYSORPTASE® is a recombinant human hyaluronidase (rHuPH20) synthesized in vitro using mammalian cells. It can locally degrade subcutaneous hyaluronic acid (HA), temporarily removing barriers to fluid flow, breaking through the subcutaneous injection volume limit of 2mL, and enabling the safe and efficient absorption of up to 1L of medication through the subcutaneous route. This improves patient experience, increases healthcare system efficiency, and enhances the competitiveness of partnered drugs.
By using HYSORPTASE® to develop co-formulations with biologics or small molecule drugs, co-formulated medications can overcome subcutaneous injection volume limitations, enabling rapid, convenient, and safe high-dose administration. This provides benefits to patients, healthcare systems, and manufacturers.
Several subcutaneous injection products using similar hyaluronidase co-formulation technology have been recognized in the global market.